Women With a Partial Mole During Their First Pregnancy and Diagnosed Earlier in Gestation Are at Increased Risk of Developing Gestational Trophoblastic Neoplasia

Objective The aim of this study is to identify factors associated with gestational trophoblastic neoplasia (GTN) after partial molar pregnancy. Methods We retrospectively evaluated clinical data from 111 patients with a partial molar pregnancy between 1995 and 2010. Results A total of 111 patients with a partial molar pregnancy were available for analysis. There was no significant difference between patients who did and did not develop GTN with respect to patient age, parity, history of prior molar pregnancy, presenting signs/symptoms, uterine size greater than gestational age, clinical diagnosis, preevacuation sonogram findings, or the preevacuation human chorionic gonadotropin value. Patients who developed GTN had fewer prior pregnancies (median, 2 vs 3; P = 0.02) and were more likely to have had a partial molar pregnancy as their first gestational event (37.1% vs 17.1%; P = 0.03). Among the 35 patients who developed GTN, the median time to diagnosis of GTN was 47 days (range, 25–119 days), and the median human chorionic gonadotropin value at the time of GTN diagnosis was 475 mIU/mL (range, 20–52,630 mIU/mL). All women (100%) who developed GTN had stage I disease, and all patients (100%) had low-risk GTN. All 35 women (100%) were able to achieve remission, and most (85.7%) of these patients received methotrexate as first-line chemotherapy. Conclusions Women with a partial molar pregnancy as their first gestational event and diagnosed earlier in gestation are more likely to develop postmolar GTN.

[1]  P. S. Lim,et al.  Outcome of molar pregnancies in Malaysia: A tertiary centre experience , 2013, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[2]  J. Lurain Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. , 2010, American journal of obstetrics and gynecology.

[3]  R. Berkowitz,et al.  Molar pregnancy: pathology and management , 2008 .

[4]  R. Berkowitz,et al.  Current management of gestational trophoblastic diseases. , 2009, Gynecologic oncology.

[5]  Y. Xiang,et al.  Changes of clinical features in hydatidiform mole: analysis of 113 cases. , 2008, The Journal of reproductive medicine.

[6]  H. Boussen,et al.  Gestational trophoblastic disease in Tunisia. , 2008, La Tunisie medicale.

[7]  R. Berkowitz,et al.  Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. , 2006, The Journal of reproductive medicine.

[8]  R. Berkowitz,et al.  Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. , 2006, The Journal of reproductive medicine.

[9]  B. Hancock,et al.  Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. , 2006, The Journal of reproductive medicine.

[10]  L. Sunde,et al.  Predictors of Low Risk of Persistent Trophoblastic Disease in Molar Pregnancies , 2006, Obstetrics and gynecology.

[11]  M. Quinn,et al.  Persistent trophoblast disease following partial molar pregnancy , 2006, The Australian & New Zealand journal of obstetrics & gynaecology.

[12]  E. Kohorn Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. , 2002, The Journal of reproductive medicine.

[13]  R. Berkowitz,et al.  Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. , 2002, The Journal of reproductive medicine.

[14]  J. Tidy,et al.  Current management of molar pregnancy. , 2002, The Journal of reproductive medicine.

[15]  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  R. Mclellan,et al.  Gestational trophoblastic disease. , 2001, Obstetrics and gynecology clinics of North America.

[17]  R. Berkowitz,et al.  Gestational Trophoblastic Disease , 2007, Current treatment options in oncology.

[18]  M. Seckl,et al.  Choriocarcinoma and partial hydatidiform moles , 2000, The Lancet.

[19]  A. Ayhan,et al.  Predictors of persistent disease in women with complete hydatidiform mole. , 1996, The Journal of reproductive medicine.

[20]  S. Lawler,et al.  Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole , 1990, The Lancet.

[21]  R. Berkowitz,et al.  Persistent gestational trophoblastic tumor after partial hydatidiform mole. , 1990, Gynecologic oncology.

[22]  R. Berkowitz,et al.  Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease , 1986 .

[23]  R. Berkowitz,et al.  Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. , 1986, Gynecologic oncology.